TLRY - Tilray Sales Blast Higher in Mixed Q3
Tilray (NASDAQ: TLRY) released its Q3 of fiscal 2019 results after market close on Tuesday. In contrast to fellow marijuana stock Aleafia Health (OTC: ALEAF), which reported its own Q3 figures that morning, Tilray's stock price did not move violently on the news.
In its Q3, Tilray's revenue amounted to just over $51 million. That was up by 11% from the Q2 tally, and represented a nearly 410% improvement on a year-over-year basis. On the bottom line, net loss deepened slightly to $35.7 million ($0.36 per share). Tilray's Q2 net loss was $35.1 million, while Q3 2018's deficit was $18.7 million.
Image source: Getty Images.